Pink Sheet is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Juno Therapeutics Inc. (cancer immunotherapies) closed its second huge financing in less than 12 months. The company raised $134mm through its Series B round from all existing major investors (Arch Venture Partners and Crestline Investors were key Series A participants) as well as ten public mutual funds and health care-focused funds. Juno's Series A round closed in April bringing in a whopping $176mm; proceeds from both financings are funding Juno's pipeline of chimeric antigen receptor and T-cell receptor therapies.
Gene Therapy, Cell Therapy
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?